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Abstract
Background/aims: The analyses of randomised controlled trials with missing data typically assume that, after conditioning
on the observed data, the probability of missing data does not depend on the patient’s outcome, and so the data are ‘missing
at random’ . This assumption is usually implausible, for example, because patients in relatively poor health may be more likely
to drop out. Methodological guidelines recommend that trials require sensitivity analysis, which is best informed by elicited
expert opinion, to assess whether conclusions are robust to alternative assumptions about the missing data. A major barrier
to implementing these methods in practice is the lack of relevant practical tools for eliciting expert opinion. We develop a
new practical tool for eliciting expert opinion and demonstrate its use for randomised controlled trials with missing data.
Methods: We develop and illustrate our approach for eliciting expert opinion with the IMPROVE trial (ISRCTN
48334791), an ongoing multi-centre randomised controlled trial which compares an emergency endovascular strategy
versus open repair for patients with ruptured abdominal aortic aneurysm. In the IMPROVE trial at 3 months post-rando-
misation, 21% of surviving patients did not complete health-related quality of life questionnaires (assessed by EQ-5D-3L).
We address this problem by developing a web-based tool that provides a practical approach for eliciting expert opinion
about quality of life differences between patients with missing versus complete data. We show how this expert opinion
can define informative priors within a fully Bayesian framework to perform sensitivity analyses that allow the missing data
to depend upon unobserved patient characteristics.
Results: A total of 26 experts, of 46 asked to participate, completed the elicitation exercise. The elicited quality of life
scores were lower on average for the patients with missing versus complete data, but there was considerable uncer-
tainty in these elicited values. The missing at random analysis found that patients randomised to the emergency endovas-
cular strategy versus open repair had higher average (95% credible interval) quality of life scores of 0.062 (20.005 to
0.130). Our sensitivity analysis that used the elicited expert information as pooled priors found that the gain in average
quality of life for the emergency endovascular strategy versus open repair was 0.076 (20.054 to 0.198).
Conclusion: We provide and exemplify a practical tool for eliciting the expert opinion required by recommended
approaches to the sensitivity analyses of randomised controlled trials. We show how this approach allows the trial analy-
sis to fully recognise the uncertainty that arises from making alternative, plausible assumptions about the reasons for
missing data. This tool can be widely used in the design, analysis and interpretation of future trials, and to facilitate this,
materials are available for download.
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Introduction
In randomised controlled trials (RCTs), outcome data
are typically missing for some participants. Patient-
reported outcomes such as health-related quality of life
(QoL) are particularly prone to missing data because
patients may fail to complete follow-up question-
naires.1,2 Missing data can reduce the power and effi-
ciency of an RCT and also lead to biased effectiveness
estimates.3–6 In the primary trial analysis, studies are
recommended to take an approach that is valid under
plausible assumptions about the missing data.7 Rather
than assuming that the data are ‘missing completely at
random’ (MCAR), the primary analysis should assume
they are ‘missing at random’ (MAR), that is, the prob-
ability of missing data does not depend on the patient’s
outcome, after conditioning on the observed variables
(e.g. the patients baseline characteristics). However, the
MAR assumption may be implausible in many settings;
for example, patients in relatively poor health may be
less likely to complete the requisite questionnaires, and
so these outcome data may be ‘missing not at random’
(MNAR). As the true missing data mechanism is
unknown given the data at hand, it is important to
examine whether the study results are robust to alterna-
tive assumptions about the missing data.
The US National Research Council (NRC) report
on missing data in clinical trials recommended sensitiv-
ity analyses that recognised the data could be MNAR,8
in line with general methodological guidance for deal-
ing with missing data,9 and previous specific advice for
intention-to-treat analysis in RCTs.6 However, sys-
tematic reviews report that in practice RCTs do not
handle missing data appropriately.10,11
A simple approach to sensitivity analysis is to
include in the statistical model parameters representing
outcome differences between individuals with complete
versus missing data and explore how inference vary as
these ‘sensitivity parameters’ take on specific values.12
The results and conclusions can then be compared over
a plausible range of values, possibly including a ‘tip-
ping-point’ at which the results change. However, draw-
backs of this approach are (1) for each sensitivity
analysis the sensitivity parameters are treated as known,
without uncertainty; (2) the challenge of determining
what constitutes a plausible range, and relative diffi-
culty of making statistical model parameters accessible
to non-statistical experts; (3) the extent to which some
values should be considered more plausible; and (4) the
difficulty that the plausibility of parameters/tipping
points are often assessed after the experts have seen the
preliminary analyses. An alternative is to allow experts
to quantify their views, rather than those of others. Not
only is this likely to be more intuitive and attractive for
them, but (as we show in this article) it allows us to take
a fully Bayesian approach and properly capture and
reflect expert opinion (and associated uncertainty)
about the missing data in the posterior estimate of the
treatment effect and its credible interval.
This is particularly useful for those needing a quanti-
tative summary of the trial, such as systematic
reviewers, decision makers and health providers,
because it provides a quantitative summary of how
those involved in the study (experts) would interpret its
results given the missing data. When reviewing the
study, experts will automatically (implicitly) ‘fill in’ the
gaps created by the missing data to arrive at their con-
clusions. The proposed elicitation approach coupled
with a Bayesian analysis allows the study to coherently
quantify the impact of incorporating expert knowledge
about the missing data, through to the estimates of
treatment effectiveness.
The Bayesian approach allows uncertainty about the
missing data mechanism to be propagated through the
eventual estimates of relative effectiveness. Such sensi-
tivity analyses require practical tools to facilitate expert
elicitation, and recent research, for example, the
Sheffield Elicitation Framework and associated web-
based elicitation tool,13,14 has focused on elicitation
approaches within group meetings. As Hampson
et al.15 illustrate, group-level elicitation has advantages
for training and clarification and facilitates behavioural
aggregation, such as Delphi processes, for achieving
consensus.16 However, because of the ‘feedback’ loop,
these approaches are costly in both money and time,
and in many RCTs, it may be infeasible to elicit opin-
ion from a sufficient number and range of experts. To
improve the uptake of recommended approaches to
sensitivity analysis for missing data within RCTs
requires that more accessible, practical tools for elicit-
ing and synthesising expert opinion are developed and
exemplified.8
This article directly addresses this gap in the litera-
ture, by developing a practical elicitation tool for elicit-
ing the expert opinion required for sensitivity analysis
that allows for data to be MNAR. The tool can quickly
elicit views from tens of experts, who have limited time
to devote to the elicitation exercise. We illustrate our
elicitation tool with the motivating example of
Immediate Management of the Patient with Rupture:
Open Versus Endovascular strategies (IMPROVE), an
ongoing multi-centre trial with a parallel design which
evaluates the effectiveness of an emergency endovascu-
lar strategy (eEVAR) compared with open repair
(OPEN) for patients with ruptured abdominal aortic
aneurysm (ISRCTN 48334791, www.improvetrial.org).
In the IMPROVE trial, 21% of patients did not com-
plete follow-up EQ-5D-3L questionnaires at 3 months
post-randomisation.
The article proceeds as follows: section ‘Motivating
study: the IMPROVE trial’ outlines the IMPROVE
trial and the requirements for the elicitation exercise.
Sections ‘Development of the elicitation tool’ and
‘Eliciting and synthesising expert opinion’ explain how
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the elicitation tool was developed and used. Section
‘Results’ gives the results. Section ‘Discussion’ discusses
the findings in the context of related research and out-
lines areas for further research.
Motivating study: the IMPROVE trial
The IMPROVE trial recruited 613 patients from 30
sites (29 in the United Kingdom, 1 in Canada). The
published analyses found that there was no difference
in the primary endpoint of 30-day mortality between
the randomised arms,17 but that patients with ruptured
aneurysms who were randomised to the eEVAR strat-
egy had on average, a clinically significant improvement
in their QoL score at both 3 and 12 months versus those
randomised to open repair.18 The QoL assessment used
the EQ-5D-3L19 questionnaire which requires patients
to describe their own health according to five dimen-
sions: mobility, self-care, usual activities, pain or dis-
comfort and anxiety or depression, with the option of
three levels of severity: ‘no problems’, ‘some problems’
and ‘extreme problems’. The responses to these ques-
tions are then combined with preference values from
the published literature,20 to provide QoL index scores
on a scale anchored at 1 (perfect health) and 0 (death)
with health states judged worse than death assigned a
negative value. The published analyses used multiple
imputation to handle the missing data assuming MAR,
so it is unclear whether the reported gain in average
QoL for the eEVAR strategy is robust to plausible
departures from MAR.
We use expert elicitation to recognise that the
follow-up QoL data in IMPROVE may be MNAR. At
3 months, eligible patients in both randomised arms
failed to return completed QoL questionnaires. As it is
anticipated that the patients’ response to treatment will
differ, for example, hospital stay will be longer for the
open repair arm compared to the eEVAR arm, it is
plausible that the reasons for the missingness and asso-
ciated missing values also differ by intervention.
Therefore, we elicited expert beliefs about expected
QoL differences between patients with missing versus
fully observed QoL data for patients in each arm. Our
elicitation was restricted to eligible survivors, that is,
those with confirmed ruptured aneurysms who had sur-
vived up to 3 months.18 If differences in mortality rates
between the two arms had been found, these would
feed through into quality-adjusted life years, but there
would be no implications for the elicitation or analysis
method.
Ethical approval for this study
Ethical approval was given by the London School of
Hygiene and Tropical Medicine observational research
ethics committee. Also, this study was approved by the
IMPROVE Trial Management Committee.
Pattern-mixture model
Missing data that are MNAR may be modelled with
selection models or pattern-mixture models.9 To
encourage uptake of these sensitivity analyses in RCTs,
we adopt a pattern-mixture approach. This is because
in our dealings with regulators and trial statisticians in
academia and industry, we have found the underlying
assumptions are more accessible to those interpreting
the results of RCTs. Consistent with the published
analysis, we undertake an intention-to-treat analysis
and estimate the effect of randomised arm on QoL at 3
months for eligible patients.
In our example, the pattern-mixture model allows
the mean QoL to be calculated differently according to
whether the QoL is observed (pattern 1) or missing
(pattern 2). For pattern 1, we can calculate the mean
response for each arm from the observed data (m).
However, for pattern 2, the outcome data are missing,
and so we calculate the mean to be that for pattern 1
plus an offset (d). As shown in Figure 1, the effective-
ness of treatment can then be estimated by weighting
the mean QoL scores in each pattern using the propor-
tion of patients with missing data in each arm (p). The
offset term, also known as a sensitivity parameter, may
well differ according to prognostic factors. So in the
IMPROVE trial, dO and dE represent the difference in
QoL between those who did and did not complete the
questionnaire for the eEVAR and OPEN arms, respec-
tively. A key concern is that they cannot be estimated
from the observed data.
What information is required?
To estimate treatment effectiveness, recognising that
data may be MNAR, we require expert opinion about
the likely values of the difference in the mean QoL
between patients who did and did not complete the
QoL assessment. This comparison will be made for
patients who are similar according to characteristics
that we have observed, such as age, gender and baseline
disease severity. We will also make this comparison to
estimate this sensitivity parameter for each randomised
arm (dO and dE). To see how this might work, suppose
that an expert’s views can be summarised by a mean
which gives their most likely value and a standard
deviation, which represents their uncertainty about this
value. Then, as we show in Figure 1, we could simply
substitute the mean values into the formula to provide
an estimate of treatment effectiveness that reflects this
expert’s opinion about the outcome differences between
patients with missing versus complete outcome data. In
the worked example, the expert expects patients in the
open repair arm who did not complete a questionnaire
to have a lower QoL score than those who did. The net
effect of including this elicited value for this sensitivity
parameter is that the average effectiveness of eEVAR is
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somewhat larger than in the MAR analysis. As the
worked example shows, the expert’s uncertainty about
the missing values can be propagated through into the
estimates of effectiveness. The worked example in
Figure 1 uses standard formulae, but we would like to
perform a more sophisticated analysis incorporating
elicited information from multiple experts, adjusting
for observed differences in baseline characteristics and
correlations in the QoL scores between the trial arms.
Using the same principles, we show how Bayesian
methods can provide a practical way of implementing
these improvements.
This approach to missing data requires that beliefs
are elicited from those experts with knowledge about
the likely outcomes of patients who did not complete
QoL questionnaires. We identified 46 potential experts,
who were principal investigators (mainly consultant
vascular surgeons) or trial coordinators (vascular nurse
Figure 1. Illustration of the estimation of treatment effectiveness using a pattern-mixture model that allows for outcome data to
be MNAR.
m represents the mean QoL for patients who returned their QoL questionnaires, d represents the difference in the mean QoL between patients who
did and did not return their QoL questionnaires and p represents the proportion of patients who did not return their QoL questionnaires. E and O
indicate the eEVAR and open repair treatment groups respectively.
Simple arithmetic example that uses hypothetical elicited values to re-calculate the effectiveness of eEVAR versus open repair on
QoL score. The example uses a pattern-mixture model to allow for data that are MNAR.
Information from QoL data that are observed in the RCT:
sample mean (SE) QoL score for patients who completed QoL questionnaire
eEVAR strategy= 0:76 0:02ð Þ, open repair strategy= 0:69 0:03ð Þ
proportion of patients who did not return their QoL questionnaire
eEVAR strategy= 0:18, open repair strategy= 0:24
Information elicited from an expert:
mean (SD) of difference in mean QoL between patients who did and did not return their QoL questionnaire
eEVAR strategy= 0:01 0:04ð Þ, open repair strategy= 0:05 0:1ð Þ
Then a point estimate of the treatment difference can be calculated as
(mE +pEdE) (mO +pOdO)= (0:76 0:1830:01) (0:69 0:2430:05)= 0:08:
Assuming independence between variables, the variance (V) of the treatment difference is
V(mE)+p
2
EV(dE)+ V(mO)+p
2
OV(dO)= 0:02
2 + 0:1820:042 + 0:032+ 0:2420:12 = 0:002,
and a 95% confidence interval (CI) for the treatment difference can be estimated as
(0:08 1:9630:044, 0:08+ 1:9630:044)= ( 0:01, 0:17)
Hence using a pattern-mixture model with expert information reports an estimate of the effectiveness of eEVAR versus open repair of treatment
difference (95% CI) of 0.08 (20.01, 0.17), compared to 0.07 (0.00, 0.14) for calculations based on the observed QoL alone. Note the wider
confidence interval from using the pattern-mixture model, as this approach takes account of the uncertainty from the missing data that may be
MNAR.
360 Clinical Trials 14(4)
specialists or research nurses), had been in their post
for at least 2 years and had ongoing involvement in the
IMPROVE trial. These experts were judged likely to
have knowledge about the prognosis and outcomes of
the trial patients, beyond that recorded in the data.
Development of the elicitation tool
The main purpose of the elicitation was to quantify dif-
ferences in the mean QoL score between patients who
did and did not complete QoL questionnaires.
Specifically, we asked the experts to provide their beliefs
about QoL for ‘typical’ IMPROVE trial patients, stres-
sing that these typical patients were similar according to
observed characteristics, and the only differences
between them were the randomised arm and whether or
not they returned a completed QoL questionnaire.
Hogarth21 advised that ‘assessment techniques
should be designed both to be compatible with man’s
abilities and to counteract his deficiencies’. Following
this, our work builds on our and others’ previous work
(e.g. White et al.,22 Mason,23 and references therein)
suggesting the benefits of a graphical approach.
Whereas previous work has elicited quantiles or other
summaries from experts and then provided graphical
feedback,24,25 we made our approach more intuitive
and interactive, by allowing the expert to manipulate
the distribution directly from the start.
We developed an easy-to-use web-based elicitation
tool using Shiny, a web application framework within a
widely used statistical software, R,26,27 which could be
administered by e-mail or in conference breaks. We
minimised the administrative burden by collecting
informed consent electronically and offered a £20
Amazon gift card as a token of appreciation for com-
pleted surveys. ‘Good practice’ recommendations for
eliciting expert opinion were followed, in particular by
including a feedback question and allowing the experts
to revise their answers.28
The scale for QoL scores for the elicitation exercise
is the same as the original scale for the EQ-5D utility
score, multiplied by 100 for ease of completion. The
expert is provided with possible QoL scores for typical
patients with six exemplar diagnoses on the scale
between 220 and 100, chosen as they were anticipated
to be familiar to our experts and spanned the QoL scale
(see Figure 2). The QoL values for these diagnoses were
taken from published literature (see supplementary
material for details).
The questionnaire includes some free text questions
asking the expert to explain the basis of their views, in
terms of what they observed about the trial patients
and any other reasons. These provided some useful
context which we revisit in the discussion. The supple-
mentary material provides further detail about the elici-
tation questions.
The tool was pre-piloted to improve usability and
accessibility to our target audience, using non-clinical
London School of Hygiene and Tropical Medicine clin-
ical trials unit staff with no IMPROVE involvement.
Following this, input was provided by the Trial
Manager and Chief Investigator. At their suggestion,
fictitious cartoon patients (Alfred, Bill and Chris) were
incorporated into the elicitation questionnaire, as an
aide-memoir of the typical IMPROVE patients.
At the pilot stage, we carried out face-to-face elicita-
tions with four experts, representative of those selected
for the main elicitation. They took, on average, 20 min
to complete the survey and provided feedback that led
to wording changes for improved clarity. However, no
major alterations to the structure of the tool were sug-
gested, and the graphical approach with ‘sliders’
received favourable comments.
The final version of the elicitation can be down-
loaded from https://ajm-elicit.shinyapps.io/ElicitApp
HighQ5, and screen shots from some of the key ques-
tions are reproduced as Figure 2. The graph in the top
panel accompanies the question to elicit likely QoL
scores for a typical IMPROVE patient randomised to
the open repair strategy who did not complete the ques-
tionnaire (Bill). At this stage, the expert has already
been introduced to Alfred, a typical patient randomised
to the open repair strategy, but who did return a com-
pleted QoL questionnaire: Alfred’s score is known and
marked on the QoL scale. The expert is asked for the
most likely value of Bill’s score and to indicate graphi-
cally their uncertainty about this value: the blue curve
changes dynamically as the expert moves sliders. The
graph in the middle panel is for the corresponding ques-
tion about a typical patient randomised to the eEVAR
strategy who did not complete their questionnaire
(Chris). The bottom panel shows the feedback provided
to the expert about the implications of their answers in
terms of the differences between the QoL scores for
patients who did not complete a QoL questionnaire and
were assigned to the OPEN (Bill) and eEVAR (Chris)
arms respectively, assuming that the elicited distribu-
tions for the OPEN and eEVAR arms are not related.
To allow for the possibility that the elicited values in
the two arms are related, for example, a high QoL score
in the OPEN arm makes a high score in the eEVAR arm
more likely, we asked about the score in the eEVAR arm
again, but this time provided the score for the OPEN
arm (see supplementary material for further details). By
eliciting this third distribution, we had sufficient informa-
tion to formulate a joint prior for the two sensitivity
parameters allowing for correlation between them.
Eliciting and synthesising expert opinion
The chief investigator emailed a participation invitation
to all the experts identified as potential respondents,
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including a web link to the elicitation tool and the par-
ticipant information sheet. Weekly reminders were sent
throughout the following month and we offered a fur-
ther opportunity to complete the elicitation at The
Vascular Society Annual Scientific Meeting in
November 2015.
The sensitivity analysis approach required that the
uncertainty in the individual responses was recognised
Figure 2. Screen shots from the elicitation tool.
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and that these responses were then pooled. We first
specified individual bivariate normal prior distributions
for both of the sensitivity parameters using the
responses from each expert. Second, we combined the
responses across the experts using linear pooling,16
which is a method of mathematical aggregation widely
used in practice, calculating an average of the individual
distributions using equal weights. This was specified in
our Bayesian models as a mixture of the bivariate nor-
mal distributions for each expert using the WinBUGS
software.29 See supplementary material for examples
and code.
To fully explore the sensitivity of the trial results to
a range of expert opinion, we formed a ‘community’ of
priors30 comprising three pooled priors (all experts, all
doctors and all nurses). To examine the sensitivity of
the results to the full range of diversity of opinion, we
also considered two individual priors according to the
‘most sceptical’ expert (QoL score 0.2 higher for
OPEN) and the ‘most enthusiastic’ expert (QoL score
0.29 higher for eEVAR).
Results
Expert responses
Table 1 summarises the characteristics for the 26
experts who completed the survey. Over half of the
responses were provided at the conference and almost
twice as many doctors as nurses responded.
Table 2 reports the elicitation responses. Overall, for
a typical patient in the OPEN arm, the elicited QoL
scores were lower versus the corresponding average
score from the observed data, with a mean difference
of four units on the 0–100 scale. For patients with miss-
ing QoL, the mean elicited values were on average 11
units higher for patients in the eEVAR versus Open
repair arms. In general, the nurses tended to be more
optimistic than the doctors about the expected out-
comes of OPEN patients (with incomplete QoL data),
but there was less difference in their views about the
eEVAR patients. Half the experts believed the QoL
scores for non-respondents in the eEVAR and OPEN
arms were positively correlated, and all except one of
the others reported no correlation. The supplementary
material contains more detail.
As Figure 3 shows, for both trial arms, there is a
wide diversity across the experts in the elicited QoL
scores for patients with missing data. The bold black
lines indicate the result of combining the views of all
the experts in each trial arm using linear pooling.
Implications for the effectiveness of eEVAR versus
OPEN
The results of our sensitivity analysis compared to the
complete case and MAR analyses are reported in
Figure 4 as (1) the posterior probability that the
eEVAR QoL at 3 months is at least 0.03 units greater
than the OPEN QoL, where 0.03 is the minimum clini-
cally important difference,31 alongside (2) the posterior
distribution of the difference in the mean 3-month QoL
scores between the two arms. The full posterior distri-
bution is shown as a density strip, where the darkness
at a point is proportional to the probability density.32
The estimated effect of randomised arm on average
QoL score is generally similar across the alternative
approaches to the missing data, but the sensitivity anal-
ysis resulted in substantially greater uncertainty about
this mean difference. That is, the credible intervals from
the MNAR are wider than following the MAR and
Table 1. Summary of the experts’ characteristics and knowledge of the IMPROVE trial results.
All Nursesa Doctorsb
Number of responses 26 9 17
Conference response: n (%c) 15 (58%) 6 (67%) 9 (53%)
Years in current role: n (%c)
2–3 years 3 (12%) 2 (22%) 1 (6%)
4–6 years 7 (27%) 2 (22%) 5 (29%)
7–10 years 6 (23%) 2 (22%) 4 (24%)
.10 years 10 (38%) 3 (33%) 7 (41%)
Familiarity with results: n (%c)
Some familiarity 11 (42%) 8 (89%) 3 (18%)
Familiar and have read the paper 15 (58%) 1 (11%) 14 (82%)
Reported treatment difference at
3 months: n (%c)
EVAR QoL . OPEN QoL 21 (81%) 7 (78%) 14 (82%)
OPEN QoL . EVAR QoL 1 (4%) 1 (11%) 0 (0%)
No difference 2 (8%) 0 (0%) 2 (12%)
Not sure 2 (8%) 1 (11%) 1 (6%)
aIncludes vascular nurse specialists, research nurses and a consultant vascular nurse.
bIncludes consultant vascular surgeons, a consultant interventional radiologist and a vascular academic junior doctor acting as site trial coordinator.
cPercentage of column total.
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complete case analyses. These wider credible intervals
recognise the variation within and across experts in the
likely differences in outcomes for patients with missing
versus observed QoL data. The doctor and nurse sub-
group results are broadly similar to the overall result.
However, the extreme individual priors give markedly
different results and levels of uncertainty, for the ‘opti-
mistic’ expert the probability of a clinically important
difference in favour of eEVAR is 100% while the corre-
sponding probability for the ‘sceptical’ expert is 38%.
Discussion
We successfully developed and demonstrated a user-
friendly tool for eliciting the expert opinion required for
recommended sensitivity analysis for missing data. The
tool uses existing open source software and can be
administered face-to-face or online, to elicit beliefs from
reasonably large numbers of experts without imposing
an undue burden. We have shown that the elicited views
can be converted into informative priors for the sensi-
tivity parameters in a pattern-mixture model, allowing
Table 2. Summary of elicited QoL scores for IMPROVE trial patients with missing versus observed data.
All Nursesa Doctorsb
Number of responsesc 25 8 17
Elicited scores: mean (SD)
Typical OPEN arm patient, who did not return a completed QoL questionnaire
Most likely QoL score (mean of normal distribution) 61 (17) 71 (10) 56 (17)
Uncertainty about QoL score (SD of normal distribution) 16 (12) 18 (14) 15 (11)
Typical eEVAR arm patient, who did not return a completed QoL questionnaire
Most likely QoL score (mean of normal distribution) 72 (15) 76 (11) 70 (17)
Uncertainty about QoL score (SD of normal distribution) 15 (12) 18 (13) 14 (12)
Differences in scores: mean (SD)
Typical OPEN arm patients, did not return QoL – did return QoL 24 (17) 6 (10) 29 (17)
Typical did not return QoL patients, eEVAR arm – OPEN arm 11 (11) 4 (12) 14 (10)
Correlation between QoL scores for non-respondents in the eEVAR and OPEN arms n(%d)
Positive 13 (52%) 3 (38%) 10 (59%)
Zero 11 (44%) 5 (62%) 6 (35%)
Negative 1(4%) 0(0%) 1(6%)
SD: standard deviation; eEVAR: emergency endovascular strategy; QoL: quality of life.
The QoL scale is from 220 to 100, and mean (SD) is across experts.
aIncludes vascular nurse specialists, research nurses and a consultant vascular nurse.
bIncludes consultant vascular surgeons, a consultant interventional radiologist and a vascular academic junior doctor acting as site trial coordinator.
cExcludes one nurse who expressed almost complete uncertainty about the quality of life scores.
dPercentage of column total.
Figure 3. Individual and pooled prior distributions for patients randomised to eEVAR and open repair arms: (a) eEVAR: all experts
and (b) OPEN: all experts.
Thin grey lines = individual priors, thick black lines = smoothed pooled priors across all experts.
Although each individual prior has been elicited as a normal distribution, this restriction does not apply to the pooled priors which are a mixture of
normal distributions.
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for correlation in the elicited values across the trial
arms. Trial data can then be re-analysed under different
MNAR assumptions to explore the robustness of the
results.
This article contributes to the literature in several
ways. First, by providing a practical tool that can
quickly elicit the views of a range of experts, this
research will help make recommended approaches to
sensitivity analyses accessible to a wide range of trial
settings. Second, the new tool goes further than those
developed previously, eliciting expert views about the
correlation between the randomised arms in the out-
comes for those with missing data. Third, the article
contributes to knowledge about the relative effective-
ness of a potentially important intervention eEVAR
versus open repair for patients with ruptured aortic
aneurysm. The sensitivity analysis builds on the previ-
ously published research in finding that eEVAR does
increase the mean QoL at 3 months post-randomisation
even after recognising that data may be MNAR.
A key reason that our elicitation exercise was suc-
cessful was because it was undertaken alongside an
active trial and annual society meeting for the clinicians
involved, which allowed for ease of access to experts
with the requisite knowledge about the patients with
missing data. Also, the study was carefully designed to
focus the elicitation exercise on gaining expert opinion
on the key parameters required to avoid creating an
exercise that was too burdensome. The qualitative ques-
tions allowed assessment of the experts’ engagement in
the exercise, indicated a general consensus that eEVAR
patients recovered more rapidly and provided reasons
for the missing outcome data according to unobserved
aspects that were therefore not accounted for in the
MAR analysis. These included degree of physical and
psychological recovery, personality of patient, lack of
family support, financial pressures, family bereavement,
social life, dislike of paperwork, forgetfulness, loss of
interest in the study and lack of appreciation of the
importance of completing the questionnaire.
Our tool has been designed to be generally applica-
ble to RCTs with different designs and with alternative
endpoints and can be extended in several ways. In
IMPROVE as in other studies, there is interest in
whether the treatment effect is modified by subgroup,
in this case according to age, gender and the Hardman
index which measures the patients’ baseline severity. A
potential extension would be to elicit expert beliefs on
the differences in average outcomes for the different
patient subgroups. Similarly, in IMPROVE, as in many
technology assessments, there is interest in the long-
term effectiveness of the intervention. While the experts
offered the view that the gain in QoL for eEVAR ver-
sus open repair would be maintained at 12 months
post-randomisation, it would be helpful to extend the
elicitation exercise to inform sensitivity analyses at mul-
tiple time points.
Our proposed elicitation tool is generalisable to
other clinical trials by adapting both the set of ques-
tions and response options. To encourage methods
uptake, R code for implementing the expert elicitation
is available in the online supplementary material.
Figure 4. Difference in mean quality of life score at 3 months between randomised arm (eEVAR - open repair) for survivors.
Each shaded rectangular strip shows the full posterior distribution of the difference in mean QoL at 3 months for survivors for one model run. The
darkness at a point is proportional to the probability density, such that the strip is darkest at the maximum density and fades into the background at
the minimum density. The posterior mean and 95% credible interval are marked.
*the posterior probability that the eEVAR QoL at 3 months is at least 0.03 greater than the open repair QoL. 0.03 is the minimum clinically
important difference.31
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Furthermore, the priors elicited from such primary
research, as undertaken alongside the IMPROVE trial,
could be ‘borrowed’ by future studies of the same inter-
vention (e.g. other eEVAR trials) to explore the robust-
ness of their conclusions. Potentially, a series of
reference priors for different disease areas could be
developed to facilitate MNAR sensitivity analysis with-
out undertaking primary elicitation exercises.
The approach could be used at the design stage, uti-
lising either previously collected priors or new priors
elicited from the trial team. Combining these with the
expected level of loss to follow-up could provide an
improved estimate of the likely impact of missing data
on the trial’s results. Hence, this approach could help
improve trial design, so that the study results are more
robust to anticipated levels of missing data.
An alternative approach is double sampling,33–35
which seeks to collect additional information from
those whose data are missing. The validity of this
approach depends on the (often untestable) assumption
of outcome stability, and re-contacting patients may
raise ethical and practical issues. However, in trials
where the main concern is in missing data for outcomes
other than QoL, where the assumption of outcome sta-
bility is more plausible, it would be interesting to con-
trast the results of double sampling with expert
elicitation.
Limitations
A potential limitation with sending by email is that
there might be compatibility issues between Rshiny and
older versions of web browsers. The flexibility of
administering the tool face-to-face helps address this
drawback.
Our elicitation tool is intended to be widely accessi-
ble to clinical investigators, and to achieve this goal, we
made several simplifying assumptions. First, we
assumed that individual expert opinion could be ade-
quately represented as a normal distribution. The
experts at the pilot stage considered this assumption
reasonable, and only two experts contributing to the
main elicitation indicated that the normal distribution
was restrictive. More generally, the elicitation literature
suggests that it may be preferable to avoid imposing a
parametric distribution that artificially constrains
beliefs.36 In future, we therefore plan to extend our eli-
citation tool to allow greater flexibility in the distribu-
tion of possible values. This restriction does not apply
to the priors used in our models, for example, the
pooled priors are a mixture of normal distributions.
Second, the elicitation exercise was undertaken after
the primary analysis concerning the outcome of inter-
est, QoL at 3 months post-randomisation, had been
published. Inevitably, experts’ priors are informed by
prior evidence and knowledge of the results of the trial
in question, and related evidence and this may influence
their views. Here, we found little difference between the
subgroup of experts who were aware of the published
results versus those who were not. Nevertheless, we rec-
ommend that this type of elicitation is carried out
before the trial results are known if at all possible.
When this is not possible, it is important that the analy-
sis investigates the likely implications for interpretation
of the results.
Future versions of the tool should improve on the
wording describing the scenarios. In particular, in
response to a reviewer’s suggestion, we recommend
altering the introductory sentences to the main ques-
tions, to sharpen the distinction between the variance
of an observation and the variance of a mean. For
example, before future use of the tool in Question 2, we
would replace the preamble wording (‘the range of val-
ues which you believe are plausible’) by the more pre-
cise, correct, wording used in asking the question (‘your
opinion of the most likely quality of life score for Bill’).
We anticipate that users of the tool will need to modify
the text and images. Such modifications need to main-
tain this distinction.
Summary
This article successfully demonstrates a general and
practical approach, for eliciting expert opinion and con-
ducting sensitivity analysis to assumptions about miss-
ing data in clinical trials.
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